Ecopetrol S.A.: STRONG OPERATIONAL AND FINANCIAL GOAL ACHIEVEMENT — Neutral
EC PRNewsWire — March 04, 2025BOGOTA, Colombia , March 4, 2025 /PRNewswire/ -- 2024 concluded with a robust operating performance that boosted our results across the company aligned with the goals set out at the beginning of the year. We introduced a solid financial and investment plan for 2025, which is the result of a rigorous planning process of the entire Ecopetrol Group, aiming to create sustainable value for our shareholders.

Stem, Inc. (NYSE:STEM ) Q4 2024 Earnings Conference Call March 4, 2025 5:00 PM ET Company Participants Ted Durbin - Head, Investor Relations Arun Narayanan - Chief Executive Office Doran Hole - Chief Financial Officer and Executive Vice President Conference Call Participants Thomas Boyes - TD Cowen Justin Clare - Roth MKM Ameet Thakkar - BMO Capital Markets Dylan Nassano - Wolfe Research Joseph Osha - Guggenheim Partners Kashy Harrison - Piper Sandler Operator Greetings and welcome to the Stem, Inc. Fourth Quarter 2024 Results Conference Call. At this time, all participants are in listen-only mode.

Royal Caribbean Group CEO Jason Liberty sits down with Jim Cramer — Neutral
RCL CNBC Television — March 04, 2025Royal Caribbean Group President and CEO Jason Liberty joins 'Mad Money' host Jim Cramer to talk the impact of tariffs on customer spending, demand in the travel sector, consumer trends, and more.

Kessler Topaz Meltzer & Check, LLP: Important Deadline Reminder for Crocs, Inc. Investors in Securities Fraud Class Action Lawsuit — Neutral
CROX GlobeNewsWire — March 04, 2025RADNOR, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against Crocs, Inc. (NASDAQ: CROX) (“Crocs” or) on behalf of investors who purchased or otherwise acquired Crocs common stock between November 3, 2022, and October 28, 2024, inclusive (the “Class Period”). This action, captioned Carretta v. Crocs, Inc., et al., Case No. 1:25-cv-00096-JLH, was filed in the United States District Court for the District of Delaware.

NeuroPace, Inc. (NPCE) Q4 2024 Earnings Call Transcript — Neutral
NPCE Seeking Alpha — March 04, 2025NeuroPace, Inc. (NASDAQ:NPCE ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Jeremy Feffer - Investor Relations Joel Becker - Chief Executive Officer and Board Member Rebecca Kuhn - Chief Financial Officer, Vice President, Finance and Administration Conference Call Participants Priya Sachdeva - UBS Rohin Patel - JP Morgan Frank Takkinen - Lake Street Capital Markets Mike Kratky - Leerink Partners Vik Chopra - Wells Fargo Matthew Park - Cantor Fitzgerald Michael Pollard - Wolfe Research Operator Greetings and welcome to NeuroPace Fourth Quarter 2024 Earnings Call. At this time, all participants are in a …

April 18, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against VG — Neutral
VG Accesswire — March 04, 2025NEW YORK, NY / ACCESS Newswire / March 4, 2025 / If you suffered a loss on your Venture Global, Inc. (NYSE:VG) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/venture-global-inc-lawsuit-submission-form?prid=133960&wire=1 or contact Joseph E. Levi, Esq.

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – GSK — Neutral
GSK Accesswire — March 04, 2025NEW YORK, NY / ACCESS Newswire / March 4, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE:GSK) between February 5, 2020 and August 14, 2022, both dates inclusive (the "Class Period"), of the important April 7, 2025 lead plaintiff deadline. SO WHAT: If you purchased GSK ADRs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA — Neutral
NTLA Accesswire — March 04, 2025NEW YORK, NY / ACCESS Newswire / March 4, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ:NTLA) between July 30, 2024 and January 8, 2025, both dates inclusive (the "Class Period"), of the important April 14, 2024 lead plaintiff deadline. SO WHAT: If you purchased Intellia securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN — Neutral
BHVN PRNewsWire — March 04, 2025NEW YORK , March 4, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd ("Biohaven" or the "Company") (NYSE: BHVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Integral Ad Science Holding Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IAS — Neutral
IAS GlobeNewsWire — March 04, 2025NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Integral Ad Science Holding Corp. (NASDAQ: IAS) between March 2, 2023 and February 27, 2024, inclusive (the “Class Period”), of the important March 31, 2025 lead plaintiff deadline.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc- PLRX — Neutral
PLRX PRNewsWire — March 04, 2025NEW YORK , March 4, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc ("Pliant" or the "Company") (NASDAQ: PLRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN — Neutral
VALN PRNewsWire — March 04, 2025NEW YORK , March 4, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teleflex Incorporated - TFX — Neutral
TFX PRNewsWire — March 04, 2025NEW YORK , March 4, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Teleflex Incorporated ("Teleflex" or the "Company") (NYSE: TFX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Lyft, Inc. (LYFT) Presents at Morgan Stanley Technology, Media & Telecom Conference (Transcript) — Neutral
LYFT Seeking Alpha — March 04, 2025Lyft, Inc. (NASDAQ:LYFT ) Morgan Stanley Technology, Media & Telecom Conference March 4, 2025 4:50 PM ET Company Participants David Risher - CEO Conference Call Participants Unidentified Analyst All right. Good afternoon, everyone.

ROSEN, A LEADING LAW FIRM, Encourages Grocery Outlet Holding Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GO — Neutral
GO GlobeNewsWire — March 04, 2025NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Grocery Outlet Holding Corp. (NASDAQ: GO) between November 7, 2023 and May 7, 2024, both dates inclusive (the “Class Period”), of the important March 31, 2025 lead plaintiff deadline.

Baytex Energy (BTE) Reports Q4 Loss, Tops Revenue Estimates — Negative
BTE Zacks Investment Research — March 04, 2025Baytex Energy (BTE) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of $0.12. This compares to earnings of $0.18 per share a year ago.

ROSEN, LEADING INVESTOR COUNSEL, Encourages Semtech Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - SMTC — Neutral
SMTC Accesswire — March 04, 2025NEW YORK, NY / ACCESS Newswire / March 4, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Semtech Corporation (NASDAQ:SMTC) between August 27, 2024 and February 7, 2025, both dates inclusive (the "Class Period"), of the important April 22, 2025 lead plaintiff deadline. SO WHAT: If you purchased Semtech securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Astronics Corporation (ATRO) Q4 2024 Earnings Call Transcript — Neutral
ATRO Seeking Alpha — March 04, 2025Astronics Corporation (NASDAQ:ATRO ) Q4 2024 Earnings Conference Call March 4, 2025 4:45 PM ET Company Participants Craig Mychajluk - IR Pete Gundermann - Chairman, President and CEO Nancy Hedges - CFO Conference Call Participants Jon Tanwanteng - CJS Securities Michael Ciarmoli - Truist Securities Operator Greetings, and welcome to the Astronics Corporation Fourth Quarter Fiscal Year 2024 Financial Results. At this time, all participants are in a listen-only mode.

Coinbase Global, Inc. (COIN) Morgan Stanley Technology, Media and Telecom Conference (Transcript) — Neutral
COIN Seeking Alpha — March 04, 2025Coinbase Global, Inc. (NASDAQ:COIN ) Morgan Stanley Technology, Media and Telecom Conference March 4, 2025 4:05 PM ET Company Participants Brian Armstrong - Co-Founder & CEO Alesia Haas - CFO Unidentified Company Representative Welcome, everyone. I don't see the disclaimer slide.

REGN DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important March 10 Deadline in Securities Class Action - REGN — Neutral
REGN Accesswire — March 04, 2025NEW YORK, NY / ACCESS Newswire / March 4, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) between November 2, 2023 and October 30, 2024, both dates inclusive (the "Class Period"), of the important March 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Regeneron securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
